Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results

Click here to go back to your search results.

Prostate Cancer treatment details. Biologic therapy. Institut Paoli-Calmettes, Marseille, France

Survival: 17.4 months
Toxicity Grade: 4
Treatments: Biologic therapy
Country: France
City/State/Province: Marseille
Hospital: Institut Paoli-Calmettes
Journal: Link
Date: 9/2008

Patients: This phase II study involved 30 men with metastatic prostate cancer. The median age was 69, ranging from 51 to 77 years old. Most (77%) had previously been treated with chemotherapy.

Treatment: Patients were treated with the biological therapy erlotinib.

Toxicity: Grade 4 anemia was reported in one patient. Grade 3 toxicities were fatigue, anemia, asthenia (weakness), diarrhea, pain, vomiting, epistaxis (nosebleed), urinary infection, urinary retention, and cutaneous toxicity (involving the skin). Grade 3 and 4 toxicities were not very common, each being reported in 1 or 2 patients.

Results: The median overall survival was 17.4 months.

Support: This study was supported by Roche, which markets erlotinib as Tarceva.

Correspondence: Dr. G. Gravis

E-mail to a Friend Email Physician More Information